Last updated: August 22, 2026
Alkeran is the original brand of melphalan, an older alkylating agent used mainly in multiple myeloma, ovarian cancer, and conditioning before autologous hematopoietic stem-cell transplantation. Its financial trajectory has followed a familiar pattern: originator erosion, product discontinuation in some markets, generic substitution, and partial value recovery through newer formulations such as Evomela.
The original Alkeran franchise has limited remaining exclusivity and weak direct pricing power. Commercial value now resides primarily in melphalan hospital use, supply reliability, formulation differentiation, and transplant-center purchasing contracts rather than in the Alkeran brand.
What is Alkeran and how is melphalan used?
Alkeran contains melphalan, a nitrogen-mustard alkylating agent that damages DNA and inhibits tumor-cell replication. It is marketed in oral and injectable forms, although availability differs by country.
| Attribute |
Alkeran and melphalan |
| Active ingredient |
Melphalan |
| Drug class |
Alkylating chemotherapy |
| Major uses |
Multiple myeloma, ovarian cancer, conditioning before stem-cell transplantation |
| Oral dosage form |
Melphalan tablets, historically 2 mg |
| Injectable dosage form |
Melphalan hydrochloride for intravenous use |
| Primary prescribers |
Hematologists, oncologists, transplant physicians |
| Main current setting |
High-dose conditioning for autologous stem-cell transplantation |
| Competitive products |
Generic melphalan injection, Evomela |
| Regulatory status |
Legacy product with market-specific availability |
| Biosimilar exposure |
None; melphalan is a synthetic small molecule |
Melphalan remains clinically relevant despite its age. Its highest-value use is often high-dose therapy before stem-cell reinfusion in multiple myeloma. That setting creates concentrated institutional demand and makes manufacturing consistency, storage, preparation time, and hospital supply continuity commercially important.
When did Alkeran lose exclusivity?
Alkeran lost practical market exclusivity many years ago. Melphalan was first introduced in the 1950s, and its core composition-of-matter and early use patents expired decades ago.
The commercial erosion timeline is broadly as follows:
| Period |
Market event |
Financial effect |
| 1950s-1980s |
Melphalan established as a chemotherapy product |
Originator-led pricing and distribution |
| 1990s-2000s |
Core exclusivity expired; generic and regional competition expanded |
Price pressure increased |
| 2000s-2010s |
Manufacturing and supply interruptions affected some markets |
Availability became a commercial differentiator |
| 2014 onward |
Alkeran tablets were discontinued in the United States |
U.S. brand revenue fell to zero or near-zero |
| 2016 |
FDA approved Evomela, a reformulated injectable melphalan product |
Premium formulation economics emerged |
| 2016-present |
Generic injectable melphalan competed with branded and reformulated products |
Market divided between price-sensitive hospitals and formulation-sensitive transplant centers |
The FDA lists Alkeran tablets as discontinued in the United States for reasons unrelated to safety or effectiveness. Discontinuation of the U.S. product removed the branded oral formulation from the principal U.S. commercial market, although melphalan remained available through other products and channels.[1]
What is the FDA regulatory status of Alkeran?
Alkeran is no longer a significant active U.S. branded product. The historical U.S. Alkeran tablet application was discontinued, and the injectable brand has also been displaced by generic and reformulated melphalan products.
Evomela was approved by the FDA in 2016 under NDA 208162. It contains melphalan for injection and uses a formulation designed to improve reconstitution and reduce dependence on propylene glycol, an excipient associated with concerns in conventional melphalan injection products.[2]
U.S. regulatory comparison
| Product |
FDA status |
Commercial position |
| Alkeran tablets |
Discontinued in the United States |
No meaningful current U.S. branded sales |
| Alkeran injection |
Legacy/discontinued or limited depending on market |
Replaced by generic and newer products |
| Generic melphalan injection |
FDA-approved products available subject to supply |
Lowest-cost conventional option |
| Evomela |
FDA-approved branded melphalan injection |
Premium formulation and transplant-focused competitor |
Market status outside the United States is less uniform. Alkeran may remain registered or distributed in selected countries, but regulatory authorization does not establish material commercial sales. Local reimbursement, tendering, supply contracts, and manufacturing arrangements determine whether the brand remains economically relevant.
What patents protect Alkeran and melphalan products?
The original Alkeran patent estate has no meaningful remaining exclusivity. Melphalan is an established generic active ingredient, and the original molecule and historical indications are long past patent expiry.
The relevant intellectual-property distinction is between:
- Core melphalan patents, which are expired.
- Product-specific formulation patents, which may have protected newer injectable products.
- Manufacturing, reconstitution, stability, and delivery claims, which can affect commercial entry without restoring broad molecule-level exclusivity.
- Method-of-use patents, which have limited relevance for a decades-old cytotoxic drug with well-established indications.
How strong is the Alkeran patent estate?
The Alkeran patent estate is weak from a current commercial-exclusivity perspective. A generic manufacturer does not need to develop a new active ingredient or establish a novel mechanism of action. The main barriers are pharmaceutical development, sterile manufacturing, regulatory compliance, supply-chain qualification, and hospital adoption.
Evomela's protection is more formulation-specific. The commercial rationale for the product has depended on its formulation and handling characteristics, not on renewed exclusivity over melphalan itself. The practical strength of such patents is narrower than a composition-of-matter patent because a competitor may be able to design around a specific formulation, excipient profile, process, or stability claim.
Are there Paragraph IV challenges to Alkeran?
There is no major current Paragraph IV controversy surrounding the original Alkeran brand. Its foundational patents expired long ago, and the U.S. Alkeran tablet product was discontinued.
Paragraph IV activity is more relevant to later melphalan products if a generic applicant challenges listed formulation or process patents. Such disputes would generally affect the branded reformulation, not the historical Alkeran molecule. Publicly disclosed litigation should be assessed against the relevant NDA and Orange Book entries rather than against the Alkeran name alone.
The absence of a meaningful current Alkeran Paragraph IV dispute reflects the age of the product and the lack of broad remaining exclusivity. It does not eliminate litigation risk for newer melphalan formulations.
What is the Orange Book status of Alkeran?
Alkeran's U.S. Orange Book relevance is limited because the historical brand products have been discontinued and the underlying active ingredient is broadly genericized.
The Orange Book may continue to contain historical application or patent information, but a listing does not mean that the product has active commercial sales or meaningful enforceable market protection. A current assessment must distinguish:
- A discontinued reference-listed drug.
- An active generic application.
- A branded reformulation with formulation patents.
- A product that has been withdrawn for commercial reasons rather than safety reasons.
For business analysis, the key conclusion is that Alkeran does not provide an effective U.S. barrier to generic melphalan entry.
Which companies compete with Alkeran and melphalan?
Competition is segmented between conventional generic suppliers and premium reformulation providers.
Generic melphalan manufacturers
Generic melphalan injection has been supplied by multiple pharmaceutical companies over time, including companies active in hospital injectables. Supplier participation has varied because sterile injectable manufacturing is more difficult than tablet production and because small oncology markets can experience intermittent shortages.
Evomela
Evomela is the principal branded reformulation competitor. It was developed and commercialized as a ready-to-use or easier-to-reconstitute alternative to conventional melphalan injection. The product's value proposition is tied to preparation, excipient profile, stability, and transplant-center workflow.
Aspen and legacy Alkeran rights
Alkeran has historically been associated with large pharmaceutical companies, including GlaxoSmithKline and Aspen Pharmacare in different commercial and regional arrangements. Ownership, licensing, distribution, and registration rights have varied by market. Public company reporting generally does not separate Alkeran revenue from broader oncology portfolios, making direct brand-level financial attribution difficult.
How has Alkeran's financial trajectory evolved?
Alkeran's financial trajectory has four phases.
Phase 1: Originator chemotherapy franchise
Alkeran generated conventional branded oncology revenue when there were few substitutes and melphalan was used across multiple cancer indications. Revenue depended on tablet and injectable sales, hospital purchasing, and specialist prescribing.
Phase 2: Generic erosion
After expiry of core patents, generic suppliers reduced the price of melphalan. The product shifted from a differentiated branded medicine to a mature hospital generic. Gross margins declined, while volume became more dependent on treatment rates and transplant activity.
Phase 3: Brand discontinuation and supply disruption
Discontinuation of Alkeran tablets in the United States removed a high-recognition originator brand from the market. Injectable supply interruptions in the broader melphalan market increased the value of reliable manufacturing but did not restore broad Alkeran exclusivity.
Phase 4: Value migration to reformulation
Evomela captured a portion of the market through product differentiation. This shifted economic value away from the original Alkeran brand and toward formulation technology, hospital contracts, and transplant-center preference.
Financial trajectory summary
| Financial driver |
Direction for original Alkeran |
Effect on newer melphalan products |
| Core patent expiry |
Negative |
Enables low-cost generic entry |
| Generic substitution |
Negative |
Compresses conventional product pricing |
| U.S. tablet discontinuation |
Negative |
Eliminates branded oral revenue in the U.S. |
| Stem-cell transplant volume |
Positive for melphalan demand |
Supports injectable market growth |
| Hospital shortages |
Mixed |
Increases value of reliable supply |
| Formulation differentiation |
Limited for Alkeran |
Supports premium pricing for Evomela |
| Reimbursement pressure |
Negative |
Favors generics in tenders and hospital systems |
| Manufacturing complexity |
Positive for incumbent suppliers |
Raises entry costs for new sterile-injectable competitors |
How large is the Alkeran market?
Public financial disclosures do not generally report Alkeran as a standalone revenue line. The product is usually grouped within broader oncology, hospital, or specialty-pharmaceutical segments.
The economically relevant market is the broader melphalan market rather than Alkeran alone. Demand is driven by:
- Multiple myeloma incidence and treatment patterns.
- Autologous stem-cell transplantation volumes.
- Use of high-dose melphalan as conditioning therapy.
- Generic availability and hospital procurement.
- Regional reimbursement rules.
- Product shortages and supplier reliability.
The market is mature in molecular terms but strategically important in transplant medicine. Demand growth is unlikely to come from new indications for Alkeran itself. Growth is more likely to track the number of transplant-eligible patients, treatment-line expansion in multiple myeloma, and continued use of melphalan-based conditioning.
What generic launch risks exist for Alkeran?
Generic launch risk for the original Alkeran product is already realized rather than prospective. The commercial threat is continuing substitution, price competition, and loss of formulary preference.
For premium melphalan formulations, generic risk is more nuanced:
| Risk |
Impact |
| Conventional generic injection |
Can undercut price |
| New formulation entrant |
Can compete on preparation and stability |
| Hospital tender consolidation |
Can reduce branded share |
| Supply shortage |
Can temporarily strengthen incumbent demand |
| Transplant-center protocol change |
Can rapidly shift product use |
| Patent design-around |
Can reduce formulation protection |
| FDA manufacturing action |
Can create shortage or market-share disruption |
A generic competitor needs to demonstrate pharmaceutical equivalence and meet sterile manufacturing standards. These requirements create operational barriers, but they do not provide durable exclusivity comparable to a novel drug patent.
What patent litigation and settlement agreements affect Alkeran?
No major current litigation or settlement agreement has materially changed the commercial position of the original Alkeran brand. The principal legal risk concerns newer melphalan formulations and any patents covering excipients, reconstitution, stability, or manufacturing processes.
Settlement economics, where applicable, would depend on:
- The scope and remaining term of formulation patents.
- Whether the challenger receives a license or an agreed launch date.
- The availability of alternative non-infringing formulations.
- The commercial value of the premium product relative to generic melphalan.
- Hospital acceptance of the competing product.
The absence of prominent Alkeran litigation is consistent with an expired core patent estate and the product's mature status.
How does Alkeran compare with Evomela?
| Factor |
Alkeran |
Evomela |
| Molecule |
Melphalan |
Melphalan |
| Product generation |
Original brand |
Reformulated product |
| Main commercial status |
Legacy or discontinued in key markets |
Active branded injectable product |
| Patent value |
Limited or expired |
Formulation-specific |
| Primary use |
Historical oral and injectable use |
Injectable use, especially conditioning |
| Pricing |
Genericized or unavailable |
Premium relative to conventional generic |
| Competitive advantage |
Clinical familiarity |
Handling, reconstitution, and formulation attributes |
| Key risk |
Substitution and discontinuation |
Generic and formulation competition |
| Revenue outlook |
Declining or immaterial as a brand |
Dependent on premium retention and transplant demand |
Evomela does not create a new melphalan market. It monetizes product differentiation within an established market. Its revenue durability depends on whether hospitals consider the operational benefits sufficient to justify a premium over conventional generic melphalan.
What geographic coverage does Alkeran have?
Alkeran's geographic position is fragmented. The brand may retain registrations, distributors, or sales in selected non-U.S. markets, while the United States relies primarily on generic or reformulated melphalan products.
Commercial exposure differs by region:
- United States: generic and reformulated injectable melphalan dominate.
- Europe: country-specific reimbursement, tendering, and marketing authorizations determine brand presence.
- Emerging markets: availability can depend on local registration, import permissions, and supply arrangements.
- Transplant centers: procurement often favors continuity of supply and protocol familiarity.
Global revenue cannot be inferred from U.S. regulatory status. A discontinued U.S. brand may continue to generate limited regional sales, but its total value is unlikely to approach that of an active patented oncology product.
What manufacturing and intellectual-property barriers remain?
The principal barriers are operational rather than molecule-level intellectual property.
Sterile injectable melphalan requires validated aseptic manufacturing, controlled handling of a cytotoxic compound, stability testing, regulatory documentation, and reliable distribution. These requirements can limit the number of suppliers even after patent expiry.
For oral tablets, the technical barriers are lower, but market economics are weaker because demand is smaller, generic substitution is extensive, and certain branded presentations have been discontinued.
The strongest defensible position in the melphalan market therefore comes from:
- Reliable sterile manufacturing.
- Formulation stability.
- Hospital and transplant-center contracts.
- Regulatory compliance.
- Documented preparation or workflow advantages.
- Supply continuity during shortages.
Key Takeaways
- Alkeran is the legacy brand of melphalan, an established alkylating chemotherapy.
- Core molecule and indication patents expired decades ago.
- U.S. Alkeran tablets were discontinued, eliminating meaningful U.S. branded oral revenue.
- The commercial market shifted to generic melphalan injection and Evomela.
- Evomela's value is based on formulation and handling advantages, not new molecular exclusivity.
- The original Alkeran brand has limited current pricing power and no material standalone exclusivity.
- Product-specific revenue is generally not separately disclosed by public companies.
- Melphalan demand remains supported by multiple myeloma treatment and autologous stem-cell transplantation.
- Future financial performance depends more on hospital procurement, supply reliability, formulation differentiation, and transplant volumes than on Alkeran branding.
- Biosimilar risk is not relevant because melphalan is a synthetic small molecule; generic and formulation competition are the relevant risks.
FAQs
Is Alkeran still sold in the United States?
The original U.S. Alkeran products have been discontinued or displaced. Melphalan remains available through generic injectable products and newer branded formulations such as Evomela.
Does Alkeran have remaining patent protection?
The original Alkeran molecule and core uses do not have meaningful remaining patent protection. Any current protection is more likely to relate to specific formulations, manufacturing methods, or newer melphalan products.
Is Evomela a generic version of Alkeran?
Evomela contains the same active ingredient, melphalan, but is a separately developed injectable formulation. It is not simply the original Alkeran product under a different name.
Does Alkeran face biosimilar competition?
No. Biosimilars apply to biological products. Melphalan is a conventional synthetic small-molecule drug and faces generic competition instead.
Is Alkeran a growth product for pharmaceutical investors?
The original Alkeran brand is generally a mature or declining asset. Investment value is more likely to reside in differentiated melphalan formulations, sterile-injectable manufacturing capacity, or broader oncology portfolios than in the legacy Alkeran brand itself.
References
-
U.S. Food and Drug Administration. (n.d.). Alkeran tablets: Drug product database and discontinuation information. FDA.
-
U.S. Food and Drug Administration. (2016). FDA approves Evomela for multiple myeloma and conditioning treatment. FDA.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Drug shortages: Melphalan hydrochloride injection. FDA.
-
National Cancer Institute. (n.d.). Melphalan. National Cancer Institute.
-
Aspen Pharmacare Holdings Limited. (2024). Integrated annual report. Aspen Pharmacare.
-
National Library of Medicine. (n.d.). DailyMed: Melphalan hydrochloride injection and oral melphalan labeling. U.S. National Library of Medicine.
